GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teligent Inc (OTCPK:TLGTQ) » Definitions » Forward PE Ratio

Teligent (Teligent) Forward PE Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Teligent Forward PE Ratio?

Teligent's Forward PE Ratio for today is 0.00.

Teligent's PE Ratio without NRI for today is 0.00.

Teligent's PE Ratio for today is 0.00.


Teligent Forward PE Ratio Historical Data

The historical data trend for Teligent's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teligent Forward PE Ratio Chart

Teligent Annual Data
Trend 2015-12 2016-12 2017-11 2018-11 2019-11
Forward PE Ratio
58.14 36.76 25.84 129.87 6.77

Teligent Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-06 2017-09 2018-03 2018-09 2019-03
Forward PE Ratio 58.14 22.32 333.33 34.60 36.76 52.08 67.57 33.56 526.32 43.86 7.73

Competitive Comparison of Teligent's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Teligent's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teligent's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teligent's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Teligent's Forward PE Ratio falls into.



Teligent Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Teligent  (OTCPK:TLGTQ) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Teligent Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Teligent's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teligent (Teligent) Business Description

Traded in Other Exchanges
N/A
Address
105 Lincoln Avenue, Buena, NJ, USA, 08310
Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.
Executives
Joseph Benesch officer: VP, Controller, PAO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
Alyssa Lozynski officer: Interim CFO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310
William S Marth director 236 GROVE STREET, WELLESLEY MA 02482
Philip K Yachmetz officer: EVP, Chief Legal Off, Corp Sec 501 LAFAYETTE AVE WYCKOFF NJ 07481
R Carter Pate director 5739 WORTHAM LANE, DALLAS TX 75252
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Carole Ben-maimon director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Sabatino Thomas J Jr director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
John E Celentano director C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Steven H Koehler director C/O THE MEDICINES CO, 5 SYLVAN WAY, PARSIPPANY NJ 07054
Keith James officer: Prin Acct Officer Controller 105 LINCOLN AVENUE BUENA NJ 08310
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Donald V Weir 10 percent owner SANDERS MORRIS HARRIS, 600 TRAVIS, HOUSTON TX 77002
Timothy B. Sawyer officer: CEO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310